Evidence map›Paper›PMID 42327096›Full record

ArticlebioRxiv : the preprint server for biology2026

mTOR inhibition augments antitumor immune effector response by reprogramming the

Priyatosh Nath, Alok Khandelwal, Chun Li, Tara Moore-Medlin, Srivatsa Surya Vasudevan, Victor Albornoz Alvarez, Omar E Franco, J Silvio Gutkind, Cherie-Ann O Nathan

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Priyatosh NathDepartment of Otolaryngology-Head and Neck Surgery, Louisiana State University Health, Shreveport, Louisiana-71103, USA.
Alok KhandelwalDepartment of Otolaryngology-Head and Neck Surgery, Louisiana State University Health, Shreveport, Louisiana-71103, USA.
Chun LiDepartment of Otolaryngology-Head and Neck Surgery, Louisiana State University Health, Shreveport, Louisiana-71103, USA.
Tara Moore-MedlinDepartment of Otolaryngology-Head and Neck Surgery, Louisiana State University Health, Shreveport, Louisiana-71103, USA.
Srivatsa Surya VasudevanDepartment of Otolaryngology-Head and Neck Surgery, Louisiana State University Health, Shreveport, Louisiana-71103, USA.
Victor Albornoz AlvarezDepartment of Otolaryngology-Head and Neck Surgery, Louisiana State University Health, Shreveport, Louisiana-71103, USA.
Omar E FrancoDepartment of Biochemistry and Molecular Biology, Louisiana State University Health, Shreveport, Louisiana-71103, USA.
J Silvio GutkindDepartment of Pharmacology, School of Medicine, University of California San Diego, La Jolla, California-92093, USA.
Cherie-Ann O NathanDepartment of Otolaryngology-Head and Neck Surgery, Louisiana State University Health, Shreveport, Louisiana-71103, USA.

Funding

Project 4-Tracking cytomegalovirus-primed long-lived NK cells in salivary glandP20GM134974 · NIGMS · LOUISIANA STATE UNIV HSC SHREVEPORT · PI ANDREW D YUROCHKO · 2021 to 2026
$15.0M
Multi-institutional trial: molecular analysis of marginsR01CA102363 · NCI · LOUISIANA STATE UNIV HSC SHREVEPORT · PI NATHAN, CHERIE-ANN O · 2005 to 2015
$2.2M
NCI NIH HHS R01 CA102363NIGMS NIH HHS P20 GM134974
6 · The paper itself

Abstract

Introduction: Resistance to immunotherapy remains a major clinical challenge in Methods: We evaluated the effects of mTOR inhibitor everolimus in Results: Everolimus significantly suppressed tumor growth in syngeneic HNSCC models. At the cellular level, everolimus significantly increased intratumoral CD8+ T cell and dendritic cell (DC) infiltration while reducing the accumulation of regulatory T cells (Tregs). Mechanistically, everolimus induced a cytokine/chemokine response, marked by increased TNF-α/CXCL10 expression, leading to enhanced immune infiltration. Everolimus also inhibited the HIF-1α/VEGFA angiogenic axis, a central driver of immune exclusion and myeloid-derived suppressor cell (MDSC) recruitment. Furthermore, everolimus treatment attenuated PD-1/PD-L1 signaling by reducing PD-1 and PD-L1 expression, respectively, in T cells and tumor cells, thereby restoring T-cell cytotoxic competence. Discussion: These findings demonstrate that mTORi with everolimus reverses multiple mechanisms of immune resistance in

Indexed as

EverolimusHead and neck squamous cell carcinoma (HNSCC)mTORTP53 mutationTumor immunityTumor microenvironment (TME)

Identifiers

PMID42327096
PMCPMC13278147

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.